CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,244,783
- in 2 filings, $3.2M under 10b5-1 plans
Net −$3,244,783. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-25 | Tyagarajan Seshu Chief Technology Officer | Grant or award | +5,353 | $4.67 | $25K | 90,865 |
| 2025-06-25 | Tak Paul Peter Chief Executive Officer | Grant or award | +42,826 | $4.67 | $200K | 268,566 |
| 2025-06-25 | Manning Paul B Director | Grant or award | +1,070,663 | $4.67 | $5.0M | 2,213,069 |
| 2025-06-25 | Martell Christopher Director | Grant or award | +111,349 | $4.67 | $520K | 111,349 |
| 2025-06-25 | Loggia Nicoletta Director | Grant or award | +2,141 | $4.67 | $10K | 2,141 |
| 2025-06-25 | Barone Francesca Chief Scientific Officer | Grant or award | +4,282 | $4.67 | $20K | 100,809 |
| 2025-06-25 | Schoch Charles Chief Financial Officer | Grant or award | +5,353 | $4.67 | $25K | 43,391 |
| 2025-06-25 | Nabel Gary J. Director | Grant or award | +5,353 | $4.67 | $25K | 5,353 |
| 2025-06-25 | PAPA JOSEPH C Director | Grant or award | +64,239 | $4.67 | $300K | 64,239 |
| 2025-06-20 | Schoch Charles Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-06-17 | Benz Edward J. JR Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Gaeta Renee Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Loggia Nicoletta Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Manning Paul B Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Martell Christopher Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Nabel Gary J. Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | Nguyen Diem Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-17 | PAPA JOSEPH C Director | Grant or award · Stock Option (Right to Buy) | +14,240 | 14,240 | ||
| 2025-06-04 | Radhakrishnan Maha Director | Grant or award · Stock Option (Right to Buy) | +28,480 | 28,480 | ||
| 2025-03-19 | Tak Paul Peter Chief Executive Officer | Sale 10b5-1 | −400 | $9.00 | $4K | 225,740 |
Page 3 of 13 · 249 trades